Shares

3 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2023

Feb 13, 2024

BUY
$5.04 - $9.95 $64,910 - $128,146
12,879 New
12,879 $119,000
Q1 2021

May 17, 2021

SELL
$5.17 - $16.13 $59,413 - $185,365
-11,492 Closed
0 $0
Q4 2020

Feb 08, 2021

BUY
$4.01 - $7.58 $46,082 - $87,109
11,492 New
11,492 $62,000

Others Institutions Holding AVXL

About ANAVEX LIFE SCIENCES CORP.


  • Ticker AVXL
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 77,942,800
  • Market Cap $673M
  • Description
  • Anavex Life Sciences Corp., a clinical stage biopharmaceutical company, engages in the development of drug candidates for the treatment of central nervous system (CNS) diseases. Its lead drug candidate is ANAVEX 2-73, which is in Phase III clinical trial for the treatment of Alzheimer's disease; Phase III clinical trial to treat pediatric patien...
More about AVXL
Track This Portfolio

Track Fox Run Management, L.L.C. Portfolio

Follow Fox Run Management, L.L.C. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Fox Run Management, L.L.C., based on Form 13F filings with the SEC.

News

Stay updated on Fox Run Management, L.L.C. with notifications on news.